Mingying He

机构：Second Affiliated Hospital of Nanjing Medical University

发表论文 27 篇 · 总被引 1598 次 · h-index 11

代表论文

• Discovery of (10 R )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- 2H -8,4-(metheno)pyrazolo[4,3- h ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations (2014 · Journal of Medicinal Chemistry · 被引 593)
• Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19 (2020 · Journal of Medicinal Chemistry · 被引 535)
• Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib (2014 · Journal of Medicinal Chemistry · 被引 118)
• Palladium( ii )-catalyzed γ-selective hydroarylation of alkenyl carbonyl compounds with arylboronic acids (2018 · Chemical Science · 被引 84)
• Design and Synthesis of Functionally Active 5-Amino-6-Aryl Pyrrolopyrimidine Inhibitors of Hematopoietic Progenitor Kinase 1 (2023 · Journal of Medicinal Chemistry · 被引 40)
• Discovery of PF-07265028, A Selective Small Molecule Inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1) for the Treatment of Cancer (2024 · Journal of Medicinal Chemistry · 被引 23)